---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014103"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:09:21.025478+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TNF Pharmaceuticals shareholders approve 5x increase in authorized common shares and reverse split authorization

## Summary
- Authorized common shares increased from 250M to 1.25B, filed June 6, 2025.
- Stockholders approved reverse stock split at ratio 1-for-2 to 1-for-100, board discretion, within one year.
- Series F and F-1 preferred stock stated value increased from $1,000 to $1,100 per share, board may increase up to $1,250.
- All six director nominees elected; auditor ratification approved.
- Voting results: ~6.3M for share increase, ~6.4M for reverse split.

## SEC filing metadata
- accession: 0001641172-25-014103
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.03, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000164117225014103/0001641172-25-014103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000164117225014103/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014103
- JSON: https://secwatch.observer/filing/0001641172-25-014103.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014103.txt

## Key facts
- Governance Changes
  Q/C TECHNOLOGIES, INC.: Increased authorized common stock from 250,000,000 to 1,250,000,000 shares and corresponding change to total authorized capital stock (effective 2025-06-06).
  - Change: charter amendment
  - Effective: 2025-06-06
  source text: On June 3, 2025, TNF Pharmaceuticals, Inc. (the “Company”) reconvened its 2025 annual meeting of stockholders, which was adjourned from May 20, 2025 (the “Annual Meeting”). At the Company’s Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (the “Share Increase Amendment”) to increase the number of authorized shares of common stock, par value $0.001 per share (“Common Stock”), from 250,000,000 shares to 1,250,000,000 and to make a corresponding change to the number of authorized shares of the Company’s capital stock. Following the Annual Meeting, on June 6, 2025, the Company filed the Share Increase Amendment with the Secretary of State of the State of Delaware.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000164117225014103/0001641172-25-014103-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.